This Article Full Text Full Text (PDF) All Versions of this Article: 119/14/1933    most recent CIRCULATIONAHA.108.818617v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mehilli, J. Search for Related Content PubMed PubMed Citation Articles by Mehilli, J. Related Collections Platelet function inhibitors Catheter-based coronary interventions: stents Other Treatment Acute myocardial infarction Related Article

(Circulation. 2009;119:1933-1940.)
© 2009 American Heart Association, Inc.

Interventional Cardiology

Abciximab in Patients With Acute ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading

A Randomized Double-Blind Trial

Julinda Mehilli, MD; Adnan Kastrati, MD; Stefanie Schulz, MD; Stefan Früngel; Stephan G. Nekolla, PhD; Werner Moshage, MD; Franz Dotzer, MD; Kurt Huber, MD; Jürgen Pache, MD; Josef Dirschinger, MD; Melchior Seyfarth, MD; Stefan Martinoff, MD; Markus Schwaiger, MD; Albert Schömig, MD, for the Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators

From Deutsches Herzzentrum, Technische Universität, Munich, Germany (J.M., A.K., S.S., S.F., J.P., M.S., S.M., A.S.); 1. Medizinische Klinik rechts der Isar, Technische Universität, Munich, Germany (J.D., A.S.); Klinikum Traunstein, Traunstein, Germany (W.M.); Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany (F.D.); Klinik und Poliklinik für Nuklearmedizin rechts der Isar, Technische Universität, Munich, Germany (S.G.N., M.S.); and 3. Medizinische Klinik, Wilhelminenspital Vienna, Austria (K.H.).

Correspondence to Dr Julinda Mehilli, Deutsches Herzzentrum, Lazarettstr 36; 80636 München, Germany. E-mail mehilli{at}dhm.mhn.de

Received September 2, 2008; accepted February 9, 2009.

Background— The glycoprotein IIb/IIIa receptor inhibitor abciximab has improved the efficacy of primary percutaneous coronary interventions in patients with acute myocardial infarction. However, it is not known whether abciximab remains beneficial after adequate clopidogrel loading in patients with acute ST-segment–elevation myocardial infarction.

Methods and Results— A total of 800 patients with acute ST-segment–elevation myocardial infarction within 24 hours from symptom onset, all treated with 600 mg clopidogrel, were randomly assigned in a double-blind fashion to receive either abciximab (n=401) or placebo (n=399) in the intensive care unit before being sent to the catheterization laboratory. The primary end point, infarct size measured by single-photon emission computed tomography with technetium-99m sestamibi before hospital discharge, was 15.7±17.2% (mean±SD) of the left ventricle in the abciximab group and 16.6±18.6% of the left ventricle in the placebo group (P=0.47). At 30 days, the composite of death, recurrent myocardial infarction, stroke, or urgent revascularization of the infarct-related artery was observed in 20 patients in the abciximab group (5.0%) and 15 patients in the placebo group (3.8%) (relative risk, 1.3; 95% CI, 0.7 to 2.6; P=0.40). Major bleeding complications were observed in 7 patients in each group (1.8%).

Conclusion— Upstream administration of abciximab is not associated with a reduction in infarct size in patients presenting with acute myocardial infarction within 24 hours of symptom onset and receiving 600 mg clopidogrel.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2009 119: 1843-1845. [Extract] [Full Text]

This article has been cited by other articles:

				M. R. Le May, G. A. Wells, C. A. Glover, D. Y. So, M. Froeschl, J.-F. Marquis, E. R. O'Brien, M. Turek, A. Thomas, M. Kass, et al. Primary Percutaneous Coronary Angioplasty With and Without Eptifibatide in ST-Segment Elevation Myocardial Infarction: A Safety and Efficacy Study of Integrilin-Facilitated Versus Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (ASSIST) Circ Cardiovasc Interv, August 1, 2009; 2(4): 330 - 338. [Abstract] [Full Text] [PDF]

				L. Rajan and D. J. Moliterno Options and outcomes with different antiplatelet strategies during primary percutaneous coronary intervention Eur. Heart J., July 2, 2009; 30(14): 1687 - 1689. [Full Text] [PDF]

				A. Abdel-Latif and D. J. Moliterno Antiplatelet Polypharmacy in Primary Percutaneous Coronary Intervention: Trying to Understand When More Is Better Circulation, June 30, 2009; 119(25): 3168 - 3170. [Full Text] [PDF]

				Glycoprotein IIb/IIIa Inhibition After Clopidogrel Loading for Primary Percutaneous Coronary Intervention Journal Watch Cardiology, May 20, 2009; 2009(520): 2 - 2. [Full Text]